Aortic Stent Grafts Market By Product Type (Abdominal Aortic Stent Grafts, Thoracic Aortic Stent Grafts); By Anatomy/Procedure Type (Standard EVAR, Fenestrated and Branched EVAR, TEVAR and Hybrid Repairs); By End User (Hospitals and Tertiary Care Centers, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Aortic Stent Grafts Market will witness a steady CAGR of 8.3% , valued at USD 2.5 billion in 2024 , and projected to reach USD 4.1 billion by 2030 , confirms Strategic Market Research.

 

Aortic stent grafts aren’t just another cardiovascular product. They’re the frontline defense for aortic aneurysms—conditions that often go undetected until they become life-threatening. These grafts are deployed through minimally invasive endovascular procedures, offering an alternative to open surgery that dramatically cuts recovery time and complication rates.

 

What’s driving growth now is the convergence of three macro forces. First, global aging is accelerating, and with it, the prevalence of abdominal and thoracic aortic aneurysms. Second, surgical innovation has made EVAR (endovascular aneurysm repair) more accessible even in high-risk patient groups. And third, hospitals are under pressure to reduce length of stay and ICU usage—making minimally invasive stent grafts a high-value choice for both outcomes and costs.

 

In 2024, the strategic relevance of aortic stent grafts is shifting beyond just aneurysm management. There’s growing interest in treating traumatic aortic injuries and aortic dissections using customized or branched stent grafts. That’s opening the door to more patient-specific interventions, especially in tertiary hospitals and academic centers .

 

Also worth noting is the regulatory momentum. The U.S. FDA and European regulators have streamlined approval pathways for next-gen endografts—especially those targeting complex anatomies. This has encouraged OEMs to push the envelope with more adaptable, flexible, and long-lasting grafts designed for wider anatomical ranges.

 

Key stakeholders in this market include:

• Device manufacturers investing in low-profile, repositionable stent grafts and modular systems.

• Hospitals and surgical centers implementing hybrid ORs for complex endovascular repairs.

• Payers and insurers evaluating long-term cost savings tied to shorter hospitalizations and fewer reinterventions.

• Governments and health agencies pushing early screening initiatives for high-risk populations.

• Investors and medtech strategists watching closely as the market edges into thoracoabdominal and arch repair zones.

To be clear, this isn’t a commoditized device market anymore. The current shift is toward customization, imaging integration, and long-term durability—all aligned with rising life expectancy and chronic disease burden.

 

Market Segmentation And Forecast Scope

The aortic stent grafts market breaks down across four main dimensions—each shaped by procedural demand, device innovation, and surgical capability. These segments help explain where the market is growing, and more importantly, where the next wave of adoption might emerge.

By Product Type

• Abdominal Aortic Stent Grafts (AAA) This is the workhorse segment, used for repairing abdominal aortic aneurysms. Most EVAR procedures fall here, thanks to well-established techniques and decades of clinical data. AAA stent grafts contribute over 60% of market revenue in 2024 , but growth is steady, not explosive.

• Thoracic Aortic Stent Grafts (TAA) Used in TEVAR (thoracic endovascular aortic repair), these devices are gaining ground as surgeons expand into more complex zones, including traumatic aortic injury and dissection management. While smaller by volume, this segment is growing faster due to rising procedural confidence and improved imaging compatibility.

The TAA segment is expected to post the fastest CAGR through 2030, fueled by high-risk surgical conversions and aging populations.

 

By Anatomy / Procedure Type

• Standard EVAR For aneurysms in predictable anatomies. These are often day-case procedures in high-volume centers .

• Fenestrated and Branched EVAR (F/BEVAR) For patients with complex anatomy or near-renal involvement. These procedures are longer, costlier, and require custom or modular stent systems. But they’re opening up treatment for previously inoperable patients.

• TEVAR and Hybrid Procedures These include thoracic repairs and arch procedures sometimes paired with surgical debranching. Adoption is higher in advanced centers with hybrid ORs.

Fenestrated and branched systems are increasingly strategic, as OEMs compete on customization, seal durability, and ease of deployment.

 

By End User

• Hospitals and Tertiary Care Centers Main buyers of high-cost, image-guided grafts. These centers lead in TEVAR, hybrid procedures, and complex FEVAR cases. They demand advanced planning software, imaging integration, and post-market surveillance support.

• Ambulatory Surgical Centers (ASCs) Still limited use, mainly for standard EVAR in well-selected cases. However, this channel is expected to grow as payers push for cost containment and same-day discharge pathways become feasible.

 

By Region

• North America Mature EVAR/TEVAR landscape, high device penetration, and growing use of advanced systems for complex anatomies.

• Europe Widespread screening programs and public reimbursement support a large EVAR base. FEVAR adoption varies widely by country.

• Asia Pacific Fastest-growing region, especially in China, South Korea, and India. Expanding imaging infrastructure and surgeon training are improving procedural volumes.

• LAMEA (Latin America, Middle East, Africa) Still early-stage adoption. Most procedures done in private hospitals or academic hubs. Import tariffs and limited imaging remain barriers.

North America leads in value, but Asia Pacific is the region to watch for procedural growth.

 

Market Trends And Innovation Landscape

Aortic stent grafts may look like simple mesh tubes, but behind the scenes, this space is evolving faster than it appears. Device makers are innovating across materials, delivery systems, and imaging compatibility to meet the rising complexity of aortic disease. And clinicians are pushing the boundaries of where and how these grafts can be deployed.

Customization Is Moving Mainstream

Until recently, custom fenestrated and branched grafts were niche products, ordered for only the most complex anatomies. That’s changing. Modular systems and faster manufacturing cycles are letting more centers perform off-the-shelf customization . Some vendors now offer semi-custom stent grafts with adjustable fenestrations that can be planned and delivered in under two weeks.

According to a European vascular surgeon, “Five years ago, we avoided complex EVAR unless absolutely necessary. Now, we plan them proactively because the devices are finally catching up.”

 

Next-Gen Materials and Sealing Tech

Durability has always been a sticking point—no one wants to reintervene on a patient five years down the line. So OEMs are reengineering the basic graft fabric. Expect more use of low-porosity ePTFE and Dacron hybrids, combined with nitinol frameworks designed to anchor better without increasing radial force.

A few companies are also pushing active sealing technologies —either via polymer injection zones or shape-memory rings that adapt to irregular aortic necks. These aren’t just engineering tricks; they’re critical for long-term outcomes, especially in challenging anatomies.

 

Image-Guided Deployment and Planning Software

Advanced imaging is now central to success. Surgeons want 3D overlay, automated graft sizing, and procedural rehearsal tools. This has spurred partnerships between device manufacturers and imaging tech firms. Some platforms now offer virtual deployment simulations using a patient’s CT data—cutting down intraoperative surprises.

One emerging trend is fusion imaging , which combines fluoroscopy with real-time CT or MRI data. It’s being tested in high-volume centers to reduce contrast load and radiation exposure during TEVAR procedures.

 

Low-Profile Systems for Smaller Vessels

As more procedures shift to percutaneous access, device profiles are shrinking. The race is on to develop stent grafts that can be delivered through 14–16 Fr sheaths without sacrificing strength. This is a game changer in patients with small femoral arteries—especially women and older adults—who were previously ineligible for EVAR.

Several manufacturers are piloting hydrophilic sheath coatings and flexible delivery handles to ease navigation in tortuous anatomy. It’s small stuff technically, but it adds up to big differences in procedural success and patient eligibility.

 

AI and Predictive Planning Tools

Artificial intelligence is creeping into pre-op workflows. AI-based platforms are being used to:

• Identify ideal landing zones

• Predict endoleak risk based on morphology

• Recommend device sizes based on vessel diameter and curvature

These tools aren’t widespread yet, but in academic settings, they’re already helping younger surgeons shorten the learning curve.

Bottom line: This market isn’t just about more procedures—it’s about smarter, safer ones. The next generation of aortic stent grafts won’t just be stronger or smaller. They’ll be tailored, data-driven, and easier to use in anatomies that would’ve been written off a decade ago.

 

Competitive Intelligence And Benchmarking

The aortic stent graft market isn’t fragmented. It’s dominated by a handful of medtech giants who’ve spent years refining their device lines, clinical relationships, and global distribution networks. But make no mistake—competition is heating up, and even the leaders are being forced to evolve.

Here’s how the landscape looks:

Medtronic

Still the heavyweight. Medtronic commands a major share of the global EVAR and TEVAR market. Their strength lies in broad product availability, deep clinical data, and a massive installed base. They’re pushing hard into complex aortic cases with newer modular systems and investing in digital planning tools that integrate with CT workflows.

Strategy: Sustain dominance by offering full procedural ecosystems—from planning to post-op tracking.

 

Cook Medical

Pioneered custom-made fenestrated and branched stent grafts. Cook has long served the complex anatomy niche, especially in Europe and Australia. Their turnaround time and ability to tailor devices to patient-specific needs remain a strong differentiator, even as others chase customization.

Strategy: Stay the go-to brand for anatomically challenging cases. Build on custom device workflows.

 

Gore Medical (W. L. Gore & Associates)

Known for its flexible, conformable stent grafts and advanced sealing tech. Gore’s products often appeal to surgeons seeking easier deployment in tortuous vessels. The company’s newer low-profile delivery systems are helping it expand into standard EVAR procedures.

Strategy: Focus on ease-of-use and durability. Capture more first-time EVAR procedures with streamlined systems.

 

Terumo Aortic

A smaller player globally, but increasingly visible in hybrid and arch repair solutions. Terumo’s RelayPro platform is gaining attention for thoracic applications, particularly in Japan and select European centers . Their work in branched arch endografts could reshape TEVAR options over the next few years.

Strategy: Target TEVAR and hybrid arch procedures in high-complexity centers . Lean into anatomical coverage.

 

Endologix

Focused heavily on treating difficult AAA anatomies with alternative approaches. Their polymer-based sealing system offers a unique value proposition where standard EVAR isn’t feasible. However, uptake has been regionally limited, partly due to reimbursement hurdles.

Strategy: Own the “challenging anatomy” space where traditional fixation methods fall short.

 

JOTEC / CryoLife (now part of Artivion )

Strong footprint in Europe. They’re recognized for modular and branched graft platforms and are pushing further into hybrid OR procedures. Their arch and thoracoabdominal devices are positioned for high-end centers with skilled vascular teams.

Strategy: Expand surgical reach with modular devices for advanced anatomies. Grow through hybrid OR partnerships.

What’s changing?

• Customization is no longer a niche. Every major player is racing to offer adaptable systems for complex cases.

• Hybrid workflows matter. Vendors that offer imaging integration, AI-based planning, and follow-up tracking have a stronger hand.

• Cost pressure is real. Even in premium segments, buyers want value. Vendors offering bundled service models or AI-planning software bundled with devices are gaining attention.

To be honest, this market plays out like a chessboard—not a brawl. Each player has carved out a strategic space. But as demand shifts toward complexity, the battle will center on who can simplify it first—without sacrificing outcomes.

 

Regional Landscape And Adoption Outlook

While aortic stent grafts are used globally, the pace of adoption varies sharply by geography. Some regions have established endovascular programs and high reimbursement. Others are still figuring out how to fund or train for even standard EVAR. What’s clear is that demand is rising everywhere—just for different reasons.

North America

This remains the most mature market—particularly the United States , where EVAR and TEVAR are standard of care in most vascular centers . The presence of hybrid ORs, well-trained endovascular surgeons, and strong payer support all contribute to high procedural volumes.

The U.S. also leads in FEVAR and branched graft adoption , especially at academic hospitals. In fact, FDA-approved custom stent grafts are increasingly used for arch and thoracoabdominal repairs—areas that used to be surgical no-go zones.

One vascular surgeon in New York commented, “At this point, if you’re still doing open AAA repairs outside trauma, it’s either because you have to—or you don’t have access to the right endo tools.”

 

Europe

Europe’s adoption profile mirrors North America in many ways, but reimbursement models and approval pathways vary widely. Germany, the UK, and the Netherlands are the most advanced, with high EVAR penetration and growing use of fenestrated systems. Meanwhile, southern and eastern Europe are catching up but remain cost-sensitive.

The European Medicines Agency (EMA) has supported custom graft pathways longer than the FDA, which gives vendors like Cook Medical and Jotec a foothold in complex repairs.

Environmental regulations are also playing a role here. Lower-profile, low-radiation procedures are preferred—especially in countries with stricter hospital sustainability mandates.

 

Asia Pacific

This is the fastest-growing region , but it’s also the most uneven. Japan and South Korea have advanced vascular programs, strong domestic vendors, and widespread access to TEVAR and EVAR. In contrast, India and Southeast Asia are still scaling up endovascular capability, often limited by device cost, imaging infrastructure, and training.

That said, China is shifting gears. With a growing elderly population and government-led investment in surgical innovation, TEVAR usage is expanding rapidly—especially for thoracic dissection, which has a higher incidence in the region.

A Chinese interventionalist shared, “TEVAR has gone from rare to routine in five years. What’s holding us back now is access to truly flexible grafts for complicated cases.”

 

LAMEA (Latin America, Middle East, Africa)

Adoption here is in early stages. Brazil and Saudi Arabia lead on volume, driven by a mix of private hospitals and government initiatives. In South Africa and Egypt , EVAR is done mostly in academic or high-end private settings.

Common challenges include:

• Limited hybrid ORs

• Dependence on imports

• Lower access to advanced imaging and simulation tools

Still, donor-funded vascular programs and physician exchanges are opening the door to more procedures. There’s real opportunity here—but it’s going to take time and targeted partnerships.

The takeaway? North America and Europe own the volume today. But Asia Pacific holds the growth. The gap lies in infrastructure—and vendors who can simplify procedures, reduce profile sizes, or offer training support will find real traction in the next wave of global adoption.

 

End-User Dynamics And Use Case

Not all healthcare providers use aortic stent grafts the same way. While the technology is proven, how it's applied—and by whom—varies depending on clinical setting, budget, and patient volume. The gap between a high-end hybrid OR and a mid-tier hospital is still wide, and that has a direct impact on product choice and outcomes.

Hospitals and Tertiary Care Centers

These are the main users, especially large academic or trauma-equipped hospitals. They handle high volumes of abdominal and thoracic aortic aneurysm cases and are typically equipped with hybrid operating rooms, advanced imaging platforms, and multidisciplinary surgical teams.

In these settings, stent grafts are used for:

• Standard EVAR and TEVAR procedures

• Complex repairs using fenestrated or branched grafts

• Emergency repairs for ruptures or traumatic dissections

These users often prefer modular systems with customizable components, and they’re also early adopters of imaging software and AI-guided planning. Postoperative surveillance is also a bigger focus here, meaning long-term device performance matters more.

According to one U.S. clinical director, “When you’re running 20–30 EVARs a month, device flexibility isn’t a luxury—it’s survival.”

 

Ambulatory Surgical Centers (ASCs)

Still a niche use case—but growing. ASCs occasionally perform low-risk EVAR procedures on well-screened patients. These centers focus on fast turnaround, minimal ICU use, and short-stay pathways. They favor off-the-shelf stent grafts that are easy to deploy and require less intraoperative imaging.

That said, TEVAR and complex EVARs are rarely performed in ASCs due to the infrastructure and risk profile.

 

Veteran’s Hospitals and Government Medical Facilities

These settings often deal with budget constraints but still serve aging populations with a high burden of vascular disease. Some of these facilities participate in national screening programs for abdominal aneurysms and refer cases to tertiary centers when necessary.

Purchasing decisions here lean heavily on total cost of ownership—meaning lower reintervention rates and ease of use can be stronger selling points than just device price.

 

Use Case Highlight: Hybrid Aortic Repair in South Korea

A teaching hospital in Seoul was faced with an elderly patient suffering from both an aortic arch aneurysm and a descending thoracic dissection—an anatomy too complex for standard EVAR. The center deployed a custom branched thoracic stent graft under fusion imaging guidance in a hybrid OR.

The planning software allowed the team to simulate graft deployment and select the exact graft geometry days in advance. Intraoperatively, contrast use was reduced by 30%, procedure time was shortened, and the patient was discharged within 72 hours.

The hospital has since shifted its entire complex aortic program toward image-guided branched TEVAR, citing better outcomes and reduced ICU strain.

Bottom line: end-user behavior is shaped by more than budget. It's about capability, complexity, and patient throughput. Advanced centers will keep pushing into complex repairs. Smaller providers need systems that are simple, reliable, and supported with planning tools.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Medtronic received expanded FDA approval (2023) for its thoracic stent graft platform, now indicated for use in patients with more complex aortic anatomies, including limited access vessels.

• Cook Medical announced the launch of a modular fenestrated EVAR system in Europe (2024), designed to reduce lead time for patients with near-renal aneurysms—targeting hospitals without full custom device capabilities.

• Gore Medical initiated clinical trials in Japan (2023) for a next-gen conformable stent graft optimized for aortic arch repairs, in collaboration with national vascular surgery networks.

• Terumo Aortic unveiled a digital planning suite (2024) that integrates 3D vessel modeling and device sizing, aiming to shorten planning cycles for branched and fenestrated procedures.

• Endologix received CE mark (2023) for its polymer-sealing system adapted to smaller access vessels—making EVAR feasible in patients traditionally ruled out due to iliac size.

 

Opportunities

• Expansion of Screening Programs Countries like the U.S., UK, and Japan have national AAA screening for at-risk populations. As more governments expand early detection programs, demand for elective EVAR will follow—especially in patients with borderline anatomies.

• Rise of Complex Aortic Repairs Branched and fenestrated stent grafts are moving out of the “niche” category. Hospitals investing in hybrid ORs and training programs are starting to build entire service lines around these procedures.

• Shift to Outpatient EVAR Low-profile, repositionable grafts are making same-day discharge a reality in select cases. ASCs and hospitals under cost pressure are exploring outpatient EVAR as a pathway to lower procedural cost and faster turnover.

 

Restraints

• High Cost of Custom or Complex Grafts Fenestrated and branched systems often carry premium pricing, and not all health systems reimburse adequately. Smaller hospitals may opt for surgical repair or refer cases out—limiting broader market penetration.

• Technical Skill Gap Even with great devices, complex EVAR and TEVAR still demand deep experience. Lack of training or hybrid OR infrastructure can delay adoption, particularly in emerging economies or rural centers .

To be honest, the technology is outpacing the system in some places. Reimbursement, training, and surgical readiness need to catch up—but the direction is clear. This market isn’t just growing. It’s evolving toward smarter, more tailored interventions.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 2.5 Billion (inferred)
Revenue Forecast in 2030	USD 4.1 Billion (inferred)
Overall Growth Rate	CAGR of 8.3% (2024 – 2030) (inferred)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Anatomy/Procedure, By End User, By Geography
By Product Type	Abdominal Aortic Stent Grafts, Thoracic Aortic Stent Grafts
By Anatomy/Procedure Type	Standard EVAR, Fenestrated and Branched EVAR, TEVAR and Hybrid Repairs
By End User	Hospitals and Tertiary Care Centers, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Rise in complex aortic cases - Shift toward minimally invasive procedures - Expansion of screening programs
Customization Option	Available upon request